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JOURNAL OF HEPATOLOGYTo the Editor:
We graciously thank Drs. Ferrarese, Thalheimer, their colleagues
and the editorial board and worldwide readership of the Journal
of Hepatology for their interest in our article [1]. We are humbled
and honored by the international attention that our article has
received, and are excited by the debate that it has ignited within
the hepatology community. We have received numerous positive
correspondences regarding our review [2]. In light of recent
studies that have stirred controversy, and in anticipation of
future studies that will continue to stir controversy, we believed
a fresh objective look at the emerging evidence in the use of
beta-blockers in cirrhosis was warranted.
At our institution, our chief executive ofﬁcer frequently
impresses his mantra to ‘‘put patients ﬁrst’’ upon our entire
hospital staff [3]. As physicians, we all believe that what comes
ﬁrst is our relentless and selﬂess service and dedication to
our patients. Sometimes, this involves challenging existing
treatments when they are later found to be harmful, such as
when the same investigator who ﬁrst studied the beneﬁts of
beta-blockers in patients with cirrhosis no longer found these
beneﬁts universally applicable [4].
We have frequently cared for patients with advanced cirrhosis
who were seemingly harmed by beta-blockers once they had
fallen outside a certain ‘‘therapeutic window’’ (that had only
recently been hypothesized) [5]. Once their beta-blockers were
discontinued, azotemia, hypotension, and acute kidney injury
frequently and convincingly resolved. We were certain otherJournal of Hepatology 201
Open access under CC BY-NC-ND license.clinicians around the world must have encountered similar
experiences, yet the scientiﬁc evidence appeared to be lacking.
How could we turn our back on 30 years of highly cited landmark
studies that promoted the use of beta-blockers? Did we miss
something that was actually harming our patients?
Our article was therefore inspired by a need to re-explore the
data. We do not dispute that the beneﬁts of beta-blockers have
been well-documented in patients with cirrhosis; however, that
was not the focus of our article. We acknowledged these existing
beneﬁts and set out to more closely examine the studies that had
been ignored [6], forgotten [7], or downplayed [8,9]. What we
found was evidence – the quality of which can be debated, but
nonetheless evidence stemming from astute clinicians making
clinical observations – that beta-blockers were perhaps not as
universally indicated as even we ourselves had previously
believed. Just as the acetylsalicylic acid of cardiology has its
limitations, the ‘‘aspirin of hepatology’’ appears to have its own
pitfalls and limitations.
Even now, as this debate re-emerges, a new study from
Mandorfer and colleagues provides fresh evidence demonstrating
the detrimental effect of beta-blocker treatment after the
development of spontaneous bacterial peritonitis [10]. More
studies and debate are certain to follow.
We are extremely pleased that our review has achieved its
intended effect of renewing dialogue and reopening the scrutiny
on beta-blockers. We hope that this dialogue, along with new
research speciﬁcally focusing at studying the end-stages of4 vol. 61 j 449–455 451
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cirrhosis, will continue to be encouraged by the international
hepatology community.
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Is the pathway of energy metabolism modiﬁed in advanced cirrhosis?
To the Editor:
The role of metabolic alterations and adaptations is becoming
increasingly evident in the pathogenesis of cirrhosis and hepato-
cellular carcinoma (HCC) [1–4]. Using a rat model of cirrhosis,
Nishikawa et al. [5] demonstrate that early stage cirrhotic hepa-
tocytes switch to glycolysis to meet their energy requirements
as a result of a decline in oxidative phosphorylation, but that this
mechanism fails in late cirrhosis. Since HCC typically arises in the
background of liver cirrhosis [6] and also encompasses a glyco-
lytic phenotype [7], it would be important to determine how this
is related to the altered metabolism of cirrhotic hepatocytes.
Since early cirrhotic cells are more glycolytic than advanced or
failing cirrhotic cells, it remains unclear as to whether the
progression of HCC is facilitated by metabolically active early
cirrhotic cells or represents an escape mechanism of late cirrhotic
hepatocytes which are unable to sustain their energy demands.
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